AccessibilityHelpAbout Us
WuXi Biologics (Cayman) logo

WuXi Biologics (Cayman)(OTC) WXXWY

Market Cap$27.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)+280%
5 Year-56%
1 Year+30%
1 Month+8%
$13.33
-0.89%
-0.12Today
WuXi Biologics (Cayman) last closing stock price
MetricPriceDate
Last closeUSD 13.332026-09-23
WuXi Biologics (Cayman) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.71%USD 12.612026-09-16
1 month+7.5%USD 12.402026-08-24
3 month+58.31%USD 8.422026-06-25
Year to date+66.63%USD 8.002025-12-31
1 year+29.77%USD 10.272025-09-23
3 year+22.63%USD 10.872023-09-22
5 year-55.58%USD 30.012021-09-24
Since inception+280.3%USD 3.542017-12-18

WuXi Biologics (Cayman) Financials at a Glance

Market Cap

$27.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥43.33B

Net Income (TTM)

CN¥9.13B

EPS (TTM)

$0.34

P/E Ratio

38.65

Dividend

$0.00

Beta (Volatility)

0.94 (Low)

Price

$13.33

Volume

145,314

Open

$13.74

Previous Close

$13.33

Daily Range

$13.29 - $13.74

52-Week Range

$7.30 - $13.78

Estimated Earnings Date

Mar 23, 2027

WXXWY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About WuXi Biologics (Cayman)

WuXi Biologics (Cayman) Inc. is a leading global provider of integrated solutions for biological drug development, encompassing the entire lifecycle from discovery to manufacturing. The company serves clients worldwide, with a strong presence in China, North America, and Europe.

Products and Services
  • Comprehensive biological drug development services
  • Contract development and manufacturing organization (CDMO) for vaccines
  • Advanced testing solutions and biopharmaceutical technology consulting
Growth Outlook
  • Revenue of CNY 11.66 billion in Q2 2026, showing strong demand
  • Operating income margin of 31.6% indicates efficient operations
  • Strategic partnerships with leading biotech firms enhance market position
Financial Highlights
  • Net income of CNY 2.41 billion in Q2 2026, reflecting robust profitability
  • Gross profit margin of 46.2% demonstrates strong pricing power
  • Current ratio of 3.04 indicates solid liquidity position
WuXi Biologics has established itself as a key player in the biotechnology sector, providing essential services that support the development of innovative therapies. The company's recent financial performance highlights its ability to generate significant revenue and maintain strong profit margins, which are critical indicators of its operational efficiency and market demand. With a solid liquidity position and strategic partnerships, WuXi Biologics is well-positioned for continued growth in the evolving biopharmaceutical landscape.
AI Generated • Sep 20, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

13,252

CEO

Zhi Sheng Chen, PhD

Website

www.wuxibiologics.com

Headquarters

Wuxi, JS 214092, CN

WXXWY Financials

Key Financial Metrics (TTM)

Gross Margin

47.47%

Operating Margin

32.36%

Net Income Margin

21.20%

Return on Equity

10.51%

Return on Capital

12.83%

Return on Assets

7.66%

Earnings Yield

2.59%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$27.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.06B

Volume

145.31K

Avg. Volume

64.49K

Financials (TTM)

Gross Profit

CN¥19.60B

Operating Income

CN¥13.42B

EBITDA

CN¥16.37B

Operating Cash Flow

CN¥8.77B

Capital Expenditure

-CN¥4.12B

Free Cash Flow

CN¥4.64B

Cash & ST Invst.

CN¥13.04B

Total Debt

CN¥2.73B

WuXi Biologics (Cayman) Performance Analysis

WuXi Biologics (Cayman) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 2,267,494,59642.1%
20232023-12-31CNY 2,404,260,5846.0%
20242024-12-31CNY 2,594,948,5077.9%
20252025-12-31CNY 3,031,254,84316.8%
WuXi Biologics (Cayman) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3117.8%
Q22025-06-30-1.5%
Q42025-12-3116.7%
Q22026-06-300.3%
WuXi Biologics (Cayman) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.3026.3%
20232023-12-31CNY 0.22-27.3%
20242024-12-31CNY 0.220.0%
20252025-12-31CNY 0.3248.1%
WuXi Biologics (Cayman) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3122.9%
Q22025-06-3027.9%
Q42025-12-317.3%
Q22026-06-30-1.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥11.66B

+36.0%

Gross Profit

CN¥5.39B

+60.8%

Gross Margin

46.22%

N/A

Market Cap

$27.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.09M

N/A

Employees

13,252

N/A

Net Income

CN¥2.41B

+61.0%

EBITDA

CN¥4.34B

+75.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥13.04B

+36.9%

Total Debt

CN¥2.73B

-40.3%

Accounts Receivable

CN¥8.59B

+39.0%

Inventory

CN¥1.82B

-7.1%

Long Term Debt

CN¥2.09B

-40.1%

Short Term Debt

CN¥641.58M

-40.9%

Return on Assets

7.66%

N/A

Return on Invested Capital

13.37%

N/A

Free Cash Flow

CN¥0.00

+100.0%

Operating Cash Flow

CN¥0.00

-100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RVMDRevolution Medicines, Inc.
$190.74-1.10%
CORTCorcept Therapeutics Incorporated
$112.94-3.88%
RXDXPrometheus Biosciences, Inc.
$199.92+0.09%
NUVLNuvalent, Inc.
$123.96+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
WBDWarner Bros. Discovery
$30.76-0.23%
WHLRWheeler Real Estate Investment Trust
$5.44+190.91%
NVDANvidia
$225.51-1.47%
INTCIntel
$122.60-1.02%

Questions About WXXWY

What is the current price of WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) is trading at $13.33 per share.

What is the 52-week range for WuXi Biologics (Cayman)?

Over the past 52 weeks, WuXi Biologics (Cayman) has traded between $7.30 and $13.78.

How much debt does WuXi Biologics (Cayman) have?

As of the most recent reporting period, WuXi Biologics (Cayman) reported total debt of CN¥444.19M.

How much cash does WuXi Biologics (Cayman) have on hand?

WuXi Biologics (Cayman) reported CN¥1.32B in cash and cash equivalents in its most recent financial results.

What is WuXi Biologics (Cayman)’s dividend yield?

WuXi Biologics (Cayman) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services